Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C O Tacket

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Annals of Internal Medicine|January 15, 1991
The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials NetworkR Dolin, B S Graham, S B Greenberg, et al.
AIDS (London, England)|August 26, 1998
Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research InitiativeJ A Bartlett, S S Wasserman, C B Hicks, et al.
Infection and Immunity|May 19, 2000
Role of EspB in experimental human enteropathogenic Escherichia coli infectionC O Tacket, M B Sztein, G Losonsky, et al.
Infection and Immunity|September 1, 1997
Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and PeruD N Taylor, C O Tacket, G Losonsky, et al.
Infection and Immunity|November 24, 1999
Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccinationC O Tacket, M B Cohen, S S Wasserman, et al.
Infection and Immunity|March 20, 1999
Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in PanamaD N Taylor, J L Sanchez, J M Castro, et al.
Infection and Immunity|May 9, 1998
Validation of a volunteer model of cholera with frozen bacteria as the challengeD A Sack, C O Tacket, M B Cohen, et al.
Infection and Immunity|February 26, 2000
Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteersC O Tacket, M B Sztein, S S Wasserman, et al.
The Journal of Infectious Diseases|April 1, 1994
Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humansC Gonzalez, D Hone, F R Noriega, et al.
The American Journal of Tropical Medicine and Hygiene|January 27, 2004
Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccinesN Kanesa-Thasan, R Edelman, C O Tacket, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Annals of Internal Medicine|January 15, 1991
The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials NetworkR Dolin, B S Graham, S B Greenberg, et al.
AIDS (London, England)|August 26, 1998
Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research InitiativeJ A Bartlett, S S Wasserman, C B Hicks, et al.
Infection and Immunity|May 19, 2000
Role of EspB in experimental human enteropathogenic Escherichia coli infectionC O Tacket, M B Sztein, G Losonsky, et al.
Infection and Immunity|September 1, 1997
Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and PeruD N Taylor, C O Tacket, G Losonsky, et al.
Infection and Immunity|November 24, 1999
Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccinationC O Tacket, M B Cohen, S S Wasserman, et al.
Infection and Immunity|March 20, 1999
Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in PanamaD N Taylor, J L Sanchez, J M Castro, et al.
Infection and Immunity|May 9, 1998
Validation of a volunteer model of cholera with frozen bacteria as the challengeD A Sack, C O Tacket, M B Cohen, et al.
Infection and Immunity|February 26, 2000
Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteersC O Tacket, M B Sztein, S S Wasserman, et al.
The Journal of Infectious Diseases|April 1, 1994
Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humansC Gonzalez, D Hone, F R Noriega, et al.
The American Journal of Tropical Medicine and Hygiene|January 27, 2004
Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccinesN Kanesa-Thasan, R Edelman, C O Tacket, et al.
Pageof 9